TD Cowen Issues Positive Forecast for SiBone (NASDAQ:SIBN) Stock Price

Key Points

• TD Cowen raised SiBone’s price target to $23 from $20 and maintained a “buy” rating. Overall analyst sentiment is positive, with seven buy ratings, one sell rating, and a consensus “moderate buy” rating with an average target of $24.83.
• SiBone shares rose 12.3% to $22.70 after the company reported a quarterly loss of $0.08 per share, beating estimates by $0.05, while revenue of $55.7 million slightly exceeded expectations.
• Growth indicators improved, including approximately 20% U.S. procedure-volume growth and higher adjusted EBITDA, although the company remains unprofitable. Insiders sold about $4.7 million of stock during the last quarter, which could weigh modestly on investor sentiment.

SiBone (NASDAQ:SIBN - Get Free Report) had its price objective upped by investment analysts at TD Cowen from $20.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the stock. TD Cowen's price objective would indicate a potential upside of 1.30% from the company's current price.

Several other equities research analysts also recently commented on the company. UBS Group increased their price objective on SiBone from $24.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Needham & Company LLC lowered their target price on shares of SiBone from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Tuesday. Citigroup reaffirmed a "market outperform" rating on shares of SiBone in a research report on Tuesday. Weiss Ratings upgraded shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 20th. Finally, Truist Financial increased their price target on shares of SiBone from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, October 14th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $24.83.

SiBone Stock Up 12.3%

Shares of NASDAQ SIBN traded up $2.48 during mid-day trading on Tuesday, hitting $22.70. The company had a trading volume of 491,862 shares, compared to its average volume of 615,715. The company has a market capitalization of $1.01 billion, a PE ratio of -66.57 and a beta of 0.66. The firm has a 50-day simple moving average of $19.42 and a two-hundred day simple moving average of $16.45. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. SiBone has a one year low of $11.48 and a one year high of $22.95.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.05. The firm had revenue of $55.70 million during the quarter, compared to analysts' expectations of $55.31 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. On average, equities analysts expect that SiBone will post -0.40 EPS for the current year.

Insider Activity at SiBone

In other SiBone news, CEO Laura Francis sold 51,884 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $19.46, for a total value of $1,009,662.64. Following the transaction, the chief executive officer directly owned 321,386 shares of the company's stock, valued at $6,254,171.56. This represents a 13.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey W. Dunn sold 20,000 shares of the firm's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $18.47, for a total transaction of $369,400.00. Following the sale, the director owned 16,057 shares of the company's stock, valued at $296,572.79. This trade represents a 55.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 238,371 shares of company stock worth $4,738,916 in the last quarter. Corporate insiders own 4.00% of the company's stock.

Institutional Trading of SiBone

Institutional investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC increased its holdings in shares of SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock worth $132,649,000 after purchasing an additional 2,774,795 shares during the period. Dimensional Fund Advisors LP raised its position in shares of SiBone by 41.8% in the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock valued at $7,816,000 after buying an additional 182,465 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of SiBone by 101.6% in the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company's stock valued at $5,969,000 after buying an additional 238,219 shares during the period. Squarepoint Ops LLC boosted its stake in shares of SiBone by 40.3% in the second quarter. Squarepoint Ops LLC now owns 118,128 shares of the company's stock valued at $1,928,000 after buying an additional 33,947 shares during the period. Finally, Granahan Investment Management LLC grew its position in SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock worth $21,965,000 after buying an additional 858,942 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

Key SiBone News

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Third-quarter results exceeded estimates. SiBone reported a loss of $0.08 per share, narrower than the $0.13 analyst consensus, while revenue increased 14.5% year over year to $55.7 million, slightly above expectations. The improved earnings performance may support the stock. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Growth and cash generation improved. U.S. procedure volume grew approximately 20%, the active U.S. physician base rose 16% to 1,770, adjusted EBITDA increased 32.4% to $3.0 million, and operating cash flow reached $5.9 million. SiBone ended the quarter with $146.3 million in cash. SiBone Third-Quarter Results
• Positive Sentiment: Product and reimbursement catalysts remain in place. FDA clearance for the iFuse Granite Onyx breakthrough device and new reimbursement rules that could increase hospital payments by up to approximately $50,000 for qualifying procedures may accelerate adoption.
• Neutral Sentiment: Full-year revenue guidance is essentially unchanged. SiBone forecast fiscal 2026 revenue of $231 million to $233 million, compared with the $232.2 million consensus estimate. The guidance is reassuring but does not represent a material forecast increase. The company remains unprofitable, posting a $3.6 million quarterly net loss.
• Negative Sentiment: Insiders sold shares. SVP Michael Pisetsky sold 29,665 shares for about $655,893, reducing his position by 15.28%, while Anshul Maheshwari sold 3,738 shares for $84,105. Both retained sizable holdings, but the transactions could create modest sentiment pressure. SiBone Insider Sales

SiBone Company Profile

SI-BONE, Inc NASDAQ: SIBN is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.